EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Institutional variability in testing for actionable genetic alterations in patients with stage IIIB/C or IV non-small cell lung cancer: A real-world study from the German prospective, observational, multicenter CRISP registry (AIO-TRK-0315)

Friederike C Althoff, Horst-Dieter Hummel, Konrad Kokowski, Corinna Elender, Christian Grah, Stefan Zacharias, Annette Fleitz, Martina Jänicke, Annika Groth, Paula Ludwig, Arnd Nusch, Marcel Reiser und 7 weitere

European Journal of Cancer · 2026

DOI: 10.1016/j.ejca.2026.116265 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Cancer, 2026. Verfasst von Friederike C Althoff und 18 weiteren Autor:innen. Beteiligte Einrichtung: Goethe University Frankfurt, University Hospital, Department of Medicine 2, Hematology and Oncology, Frankfurt, Germany. Electronic address: falthoff…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Genetic Testing. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MSD Sharp & Dohme GmbH, Daiichi Sankyo Europe GmbH, GSK plc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Molecular testing in NSCLC is essential for treatment selection, yet routine implementation remains inconsistent across institutions. Clinical evidence suggests that variability in testing may not be explained by patient or tumor characteristics but might be driven by institutional factors, potentially leading to adverse outcomes. We examined the extent to which variability in AGA testing is attributable to the treating institution.

Methods

We analyzed 6437 adults with stage IIIB/C or IV NSCLC enrolled in the prospective German real-world registry CRISP (2016–2022). Logistic mixed-effects models with AGA testing as the primary outcome were used to determine institutional variability across 171 institutions. Models included patient, tumor, and treatment-related fixed effects with institutions as random effects. Intraclass correlations (ICC) quantified institutional variability unexplained by other covariates. Institution type was tested in secondary analysis, and overall survival in exploratory analysis.

Findings

AGA testing was performed in 77.9 % of patients (n = 5016). Predicted probabilities for testing use ranged from 30.5 % to 93.2 % across institutions. Institutions significantly influenced testing use (p < 0.001), accounting for 21.4 % of the total variance. Variability significantly differed by institution type and was more pronounced in subgroups, e.g., squamous histology (ICC 29.5 %) and KRAS testing (ICC 34.4 %). Absence of AGA testing was independently associated with inferior survival (HRadj 1.11, 95 % CI 1.01–1.23, p = 0.029).

Interpretation

Substantial institutional variability exists in AGA testing for NSCLC, which was unexplained by patient or tumor characteristics. This objective evaluation of institution-based variability in testing may emphasize the importance of practice patterns on patient care and may therefore provide an avenue for change.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsGenetic TestingHumansFemaleMaleAgedProspective StudiesRegistriesMiddle AgedGermanyNeoplasm StagingAdultAged, 80 and overMutation

Stichwörter der Autor:innen

Access to careInstitutional variabilityMetastatic diseaseMolecular testingNon-small cell lung cancer (NSCLC)Practice patternsPrecision oncologyReal-world data

Autor:innen und Institutionen

  • Goethe University Frankfurt, University Hospital, Department of Medicine 2, Hematology and Oncology, Frankfurt, Germany. Electronic address: falthoff@med.uni-frankfurt.de.
  • Translational Oncology/Early Clinical Trial Unit (ECTU), Comprehensive Cancer Center Mainfranken and Bavarian Cancer Research Center (BZKF), National Center for Tumor Diseases (NCT), University Hospital Würzburg, Würzbu…
  • Department of Pneumonology, Bogenhausen Hospital, Munich, Germany.
  • Pneumologie, Infektiologie, Internistische Intensivmedizin, Klinik Nord im Klinikum Dortmund, Dortmund, Germany.
  • Department of Respiratory Medicine, Clinic Havelhöhe Berlin, Berlin, Germany.
  • Statistics, iOMEDICO, Freiburg, Germany.

Förderung

  • MSD Sharp & Dohme GmbH
  • Daiichi Sankyo Europe GmbH
  • GSK plc
  • Celgene Corporation
  • Novartis Pharma GmbH
  • AstraZeneca PLC
  • Pfizer BV
  • F Hoffmann-La Roche AG

Zitieren

APA

Althoff, F. C., Hummel, H. D., Kokowski, K., Elender, C., Grah, C., Zacharias, S., Fleitz, A., Jänicke, M., Groth, A., Ludwig, P., Nusch, A., Reiser, M., Pelz, H., Wiegand, J., Griesinger, F., Thomas, M., Eberhardt, W. E. E., Sebastian, M., & CRISP Registry Group (2026). Institutional variability in testing for actionable genetic alterations in patients with stage IIIB/C or IV non-small cell lung cancer: A real-world study from the German prospective, observational, multicenter CRISP registry (AIO-TRK-0315). European Journal of Cancer. https://doi.org/10.1016/j.ejca.2026.116265

Vancouver

Althoff FC, Hummel HD, Kokowski K, Elender C, Grah C, Zacharias S, et al. Institutional variability in testing for actionable genetic alterations in patients with stage IIIB/C or IV non-small cell lung cancer: A real-world study from the German prospective, observational, multicenter CRISP registry (AIO-TRK-0315). European Journal of Cancer. 2026. doi:10.1016/j.ejca.2026.116265

BibTeX
@article{Althoff2026,
  author = {Althoff, Friederike C and Hummel, Horst-Dieter and Kokowski, Konrad and Elender, Corinna and Grah, Christian and Zacharias, Stefan and Fleitz, Annette and Jänicke, Martina and Groth, Annika and Ludwig, Paula and Nusch, Arnd and Reiser, Marcel and Pelz, Henning and Wiegand, Jörg and Griesinger, Frank and Thomas, Michael and Eberhardt, Wilfried E E and Sebastian, Martin and CRISP Registry Group, CRISP Registry Group},
  title = {Institutional variability in testing for actionable genetic alterations in patients with stage IIIB/C or IV non-small cell lung cancer: A real-world study from the German prospective, observational, multicenter CRISP registry (AIO-TRK-0315)},
  journal = {European Journal of Cancer},
  year = {2026},
  doi = {10.1016/j.ejca.2026.116265}
}
Kostenlos starten →